+1. Not bad indeed. Look at % revenue growth... demonstrates (local market) revenue generation doing well.
- Q4 FY20 Operating Revenue (up 31.4% from Q4 FY19) & (up 40.8% from Q3 FY20)
- Q4 FY20 Total Revenue (up 41.0% v Q4 FY19) & (up 99.8% vs Q3 FY20)
- FY20 Operating Revenue (up 17.0% from FY19)
- FY20 Total Revenue (up 20.8% from FY19)
Operating Costs Q4 FY20 $1.095m improved from Q3 FY20 $2.668m from better cost management, granted yes, a significant amount of it is boosted by government grants and incentives. This is operating steadily but agree... would love to see international revenues start contributing for this to fly. $MDR reporting Asia being on track to deliver revenue next quarter is promising. Keep watching.
Ann: MedAdvisor June 2020 Quarterly Activities Report, page-3
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
0.010(2.25%) |
Mkt cap ! $250.8M | |||
| Open | High | Low | Value | Volume |
| 44.5¢ | 45.5¢ | 44.5¢ | $683.4K | 1.508M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7000 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 34999 | 1 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| MDR (ASX) Chart |